CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira’s Products
Correction: Extended clarification.HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide...
Month: February 2024
Voom Medical Devices Welcomes Dr. Joël Vernois as Advisor and Editor-in-Chief of Journal of Minimally Invasive Bunion Surgery (JMIBS)
NEW YORK--(BUSINESS WIRE)--#bunionplasty--Voom™ Medical Devices, Inc. ("Voom"), a visionary medical device company focused on new paradigms in minimally invasive bunion...
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
LAVAL, QC / ACCESSWIRE / February 1, 2024 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release fourth-quarter and full-year 2023...
New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval
Fibromyalgia candidate TNX-102 SL hits primary endpoint of daily pain reduction (p=0.00005)Combination of broad-spectrum relief and favorable tolerability seen as...
Corporate Update on Clinical Evaluation of MedMira’s Products
HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update...
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live...
Akanda Corp. Entered into Non-Binding Letter of Intent for Sale of RPK
London, United Kingdom--(Newsfile Corp. - February 1, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis...
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides – NV-387 Could be As Revolutionary as Antibiotics
SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)
Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect...
Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary...
ITM Obtains Manufacturing License in the U.S.
License will support ITM’s efforts in preparing for the commercialization of its diagnostic and therapeutic radiopharmaceutical pipeline across the U.S....
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
PITTSBURGH, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced...
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell...
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel...
Applied UV, Inc. to Develop Smart Building Technologies for Larimar City, a New Luxury Development With Six Hotels and 20,000 High-end Residences – Potential Revenues Could Total $250 Million to $300 Million
Applied UV, Inc. A Rendering of Larimar City & Resort in the Dominican Republic Max Munn, CEO of AUVI, states:...
Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference
Company Previews New SpeedPlate™ Configurations, Announces Full Commercial Release of its Micro-Lapiplasty™ System and Limited Clinical Release of its Mini-Adductoplasty™...
Panbela Announces Closing of Approximately $9.0 Million Public Offering
MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of...
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11...
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and...
Opthea Strengthens Team with Key Clinical and Regulatory Hires
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track...